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Exosomes (EXs) are cell-derived vesicles that mediate cell-cell communication and could serve as biomarkers. Here we described
novelmethods for purification andphenotyping of EXs released fromendothelial cells (ECs) and endothelial progenitor cells (EPCs)
by combining microbeads and fluorescence quantum dots (Q-dots®) techniques. EXs from the culture medium of ECs and EPCs
were isolated and detected with cell-specific antibody conjugated microbeads and second antibody conjugated Q-dots by using
nanoparticle tracking analysis (NTA) system.The sensitivities of the cell origin markers for ECs (CD105, CD144) and EPCs (CD34,
KDR) were evaluated. The sensitivity and specificity were determined by using positive and negative markers for EXs (CD63),
platelets (CD41), erythrocytes (CD235a), andmicrovesicles (Annexin V).Moreover, themethods were further validated in particle-
free plasma and patient samples. Results showed that anti-CD105/anti-CD144 and anti-CD34/anti-KDR had the highest sensitivity
and specificity for isolating and detecting EC-EXs and EPC-EXs, respectively. The methods had the overall recovery rate of over
70% and were able to detect the dynamical changes of circulating EC-EXs and EPC-EXs in acute ischemic stroke. In conclusion,
we have developed sensitive and specific microbeads/Q-dots fluorescence NTA methods for EC-EX and EPC-EX isolation and
detection, which will facilitate the functional study and biomarker discovery.
1. Introduction
Exosomes (EXs) are nanoscale extracellular vesicles that are
derived from themultivesicular endosomal cell compartment
[1–3]. Upon release, EXs may either circulate in the extra-
cellular space adjacent to the site of release or enter into
biological fluids (e.g., plasma, urine, and cerebrospinal fluid).
Recent studies have indicated that EXs carry the genetic and
proteomic contents of their parent cells [4, 5]. Moreover,
increasing evidence has demonstrated that EXs are important
mediators of cell-to-cell communication and play crucial
roles in both physiological and pathophysiological processes.
They have been shown to be involved in inflammation,
tumorigenesis, cardiovascular diseases, and so forth [6–10].
Thus, a better understanding of the phenotype of EXs in
biofluids is required.However, limited studies have shown the
isolation and detection protocols of specific EXs from bioflu-
ids. Although the conventional EX isolation techniques, such
as ultracentrifugation and density-gradient separation, can
achieve collection of EXs, these techniques cannot separate
particular phenotype of EXs from the EX compound due to
their similar size and buoyant density [11].
Microbeads are superparamagnetic particles that are con-
jugated to highly specific antibodies against a particular
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antigen on the cell surface. They are often used to isolate and
enrich specific cell subpopulations via their coated antibodies
[12]. Since EXs carry the antigens of their parent cells, it is
logical to assume that specific antigen-conjugated microb-
eads could be used for EX isolation, purification, and
enrichment. Nanoparticle tracking analysis (NTA) is a new
technology that can detect vesicles as small as 30 nm in
diameter [13, 14] and count specific subgroups of EXs using
antibodies conjugated to fluorescent probes called quantum
dots (Q-dots) [6, 15]. The application of Q-dots and fluo-
rescence NTA to phenotype specific circulating extracellu-
lar vesicles, syncytiotrophoblast-derived microvesicles, and
epithelial tumor cell-derived EXs has been demonstrated
[15, 16]. Based on these observations, we hypothesized that
cell-specific antibody conjugated microbeads combined with
fluorescence Q-dots are able to isolate and phenotype EXs
from biofluids, especially for those that exposemore than one
surface antigen of their parent cells.
In this study, for developing the methods, we used one
of the specific surface antigens of endothelial cells (ECs)
or endothelial progenitor cells (EPCs) to capture the EXs
released from cultured ECs or EPCs, and thenwe probedwith
other EC or EPC specific surface antigens to phenotype the
captured EXs. To the best of our knowledge, this is the first
work describing the combination ofmicrobeads, fluorescence
Q-dots, and NTA to detect specific EXs. Moreover, we could
accurately numerate EC-EXs and EPC-EXs from human
plasma by using the methods.
2. Materials and Methods
2.1. Preparation of EXs from Cell Culture Medium. Human
brain microvascular ECs were purchased from Cell Systems
(Kirkland, WA) and cultured in CSC complete medium con-
taining 10% serum, 2% human recombinant growth factors,
and 0.2% antibiotic solution under standard cell culture
conditions (5% CO
2
, 37∘C). Cell medium was changed twice
a week. Passages 4 to 13 of ECs were used for experiments
in this study. EPCs were purchased from Amsbio. For EC-
EX preparation, ECs were challenged with CSC medium
(Cell Systems) supplemented with 2% human recombinant
growth factors and 0.2% antibiotic solution for 24 hr. For
EPC-EX preparation, EPCs were challenged with EPC basal
medium (Amsbio) and 0.2% antibiotic solution for 24 hr.
Then, the cell medium was collected and centrifuged at 300 g
for 15min, followed by centrifugation at 2000 g for 30min to
remove cells and cell debris.The cell-free culturemediumwas
centrifuged at 20,000 g for 70min and then ultracentrifuged
at 170,000 g for 6 hr to pellet EXs. The pelleted EXs were
resuspended with 20 nm filtered (Whatman, Pittsburgh, PA)
phosphate-buffered saline (PBS) and aliquoted for NTA.
2.2. Isolation of EC-EXs and EPC-EXs from EC and EPC Cul-
tureMedium by Using Anti-CD105- or Anti-CD34-Conjugated
Microbeads. According to the manufacturer’s instruction
with modifications, the pelleted EXs were incubated with
10 𝜇L of Biotin-conjugated anti-CD105 (specific for ECs),
anti-CD41 (specific for platelets), anti-CD235a (specific for
erythrocytes), or anti-CD34 (specific for EPCs) antibody
(Miltenyi Biotec) in a 100 𝜇L reaction volume for 2 hr,
followed by adding 10 𝜇L of anti-Biotinmicrobeads (Miltenyi
Biotec), respectively. Then, a magnet module was applied
to separate microbeads-labeled EXs from the total EX sus-
pension. After an overnight magnet separation, the fluid
was gently removed from the magnet and was considered
as wastes. The microbeads bound EXs were resuspended
with 100 𝜇L filtered PBS and added with 10 𝜇L of multisort
release reagent (Miltenyi Biotec) for 10min to cleave off
the microbeads from EXs by following the manufacturer’s
instruction.Then, all samples were added with 150𝜇L filtered
PBS to bring the final volume to 250 𝜇L and were placed
at a magnet (DynaMag-2; Life technology) to get rid of
the released microbeads overnight. On the following day,
the fluid was collected and considered as CD105+, CD41+,
CD235a+, or CD34+ EXs. All isolated EXs were enumerated
by using the NTA NS300 system (Malvern Instruments).
The purification efficiency was calculated as the number of
microbead positive EXs divided by the total number of EXs.
2.3. Immunofluorescence Labeling of CD105+ EXs and CD34+
EXs with Q-Dots. The isolated CD105+ or CD34+ EXs were
then incubated with other sets of primary antibodies, goat-
against CD144 (specific for ECs), goat-against KDR (specific
for EPCs), goat-against Annexin V (specific for MVs), or
goat-against CD63 (specific for EXs) (1 : 200 dilution; Santa
Cruz Biotechnology), for 2 hr, followed by incubation with
rabbit anti-goat IgG conjugated with Q-dot 655 (1 : 350
dilution; Life Technologies) for 90min at RT. FilteredPBSwas
added to EX suspension to give a final volume of 700𝜇L. All
samples were analyzed by the NTA NS300 system (Malvern
Instruments, United Kingdom).
2.4. Nanoparticle Tracking Analysis. The NanoSight NS300
with a 405 nm laser instrument (Malvern Instruments,
United Kingdom) was used to detect EXs without label or
labeled with stable fluorophores. The NanoSight polystyrene
latex calibration beads, 100 nm and 200 nm, were applied
to check the instrument performance. In this study, diluted
suspensions containing EXs were loaded into the sample
chamber, and the camera level was maintained at 10 for light
scatter mode and at 16 for fluorescence scatter mode between
samples. Light scatter mode of NTA used the camera filter
1, and fluorescence mode used the camera filter 2 with the
long-pass 430 nm filter in place. Three videos of typically 30
seconds duration were taken, with a frame rate of 30 frames
per second. Data was analyzed by NTA 3.0 software (Malvern
Instruments) which was optimized to first identify and then
track each particle on a frame-by-frame basis.
2.5. Calculation of the Detection and Overall Efficiencies
of Double Labeled EXs. The detection efficiency of the
CD105+Q-dots+ EXs and CD34+Q-dots+ EXs was calcu-
lated as follows: (CD105+Q-dots+) EXs% = (the number of
CD105+Q-dots+ EXs)/(the total number of CD105+ EXs);
(CD34+Q-dots+) EXs% = (the number of CD34+Q-dots+
EXs)/(the total number of CD34+ EXs).The overall efficiency
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ofmeasuring the CD105+Q-dots+ EXs or CD34+Q-dots+ EXs
was calculated as follows: (CD105+) EXs% = (the number of
CD105+Q-dots+ EXs)/(the total number of EXs); (CD34+)
EXs% = (the number of CD34+Q-dots+ EXs)/(the total num-
ber of EXs).
2.6. Protein and Western Blot Assays. Proteins from EC-
EXs and EPC-EXs were isolated with lysis buffer (Thermo
Scientific, FL) containing protease inhibitor. Protein concen-
tration assay was conducted using a Bradford assay kit (Bio-
Rad Laboratories). The linear range of the assay for BSA is
from 0.2 to 0.9mg/mL. Plates were read at 595 nm using a
spectrofluorometer (BioTek Instruments). For western blot
analysis, the proteins were subjected to electrophoresis and
transferred onto PVDF membranes. The membranes were
blocked by incubating with 5% dry milk for 1 hr, followed
by incubation with primary antibodies overnight at 4∘C.
The primary antibodies used were anti-CD63 (1 : 400; BD
Biosciences), anti-CD105 (1 : 500; Santa Cruz), anti-CD34
(1 : 500, Santa Cruz), and 𝛽-actin (1 : 4000, Sigma). After
being washed thoroughly, membranes were incubated with
horseradish peroxidase-conjugated IgG (1 : 40000; Jackson
ImmunoResearch Labs) for 1 hr at room temperature. Blots
were then developed with enhanced chemiluminescence
developing solutions.
2.7. TEM of EC-EXs and EPC-EXs. The EXs collected from
EC and EPC conditioned medium were fixed with 2% glu-
taraldehyde and postfixed with 1% osmium (all were pur-
chased from ElectronMicroscopy Science, Hatfield, PA), and
then they were embedded with Spurr resin (Sigma, St. Louis,
MO) and baked at 60∘C according to the manufacturer’s
instruction and our previous study [17]. Ultrathin sections
(60–80 nm) were prepared with MT7000, mounted on 300-
mesh copper grids, and stained with uranyl acetate and lead
citrate. All samples were examined with an EM 208 (Philips)
transmission electron microscope at an accelerating voltage
of 70KV.
2.8. Recovery of EC-EXs and EPC-EXs from Particle-Free
Plasma. The human plasma was diluted 5x with filtered
PBS and centrifuged at 200 g for 20min. The supernatant
was centrifuged at 20,000 g for 70min, followed by ultra-
centrifugation at 170,000 g for 6 hr. The supernatant after
ultracentrifugation was analyzed by NTA and considered
particle-free plasma. The known amounts (6 × 108 particles)
of EC-EXs or EPC-EXs that were isolated from ECs and
EPCs were added into 1mL of prepared particle-free plasma.
The EC-EXs/particle-free plasma and EPC-EXs/particle-free
plasma mixture were centrifuged at 20,000 g for 70min
at 4∘C and then ultracentrifuged at 170,000 g for 6 hr to
pellet recovered EC-EXs and EPC-EXs. The recovered EC-
EXs and EPC-EXs were resuspended with filtered PBS and
then isolated by anti-CD105-, anti-CD34-, anti-CD41-, or
anti-CD235-conjugated microbeads and analyzed by NTA.
Likewise, the recoveredmicrobeads positive EXswere probed
with anti-CD144-, anti-Annexin V-, anti-KDR-, or anti-
CD63-conjugated Q-dots and then subsequently analyzed
by fluorescence NTA. The recovery rate was calculated as
the number of microbeads positive EXs divided by the total
number of EXs. Similarly, the detection and overall efficiency
of the recovered CD105+Q-dots+ EXs and CD34+Q-dots+
EXs were calculated as described above.
2.9. Study Subjects. This study recruited 16 ischemic stroke
patients from the Department of Neurology at the Ochsner
Medical Center. Peripheral blood (3mL) was collected from
ischemic stroke patients on admission day (day 1) after stroke
occurs. 16 patients were divided into two groups: one group
for cEC-EXs analysis (𝑛 = 8); another group was used to
detect cEPC-EXs (𝑛 = 8). Exclusion criteria of subjects for
this study included any of the following situations: (1) infec-
tious disease in a previous month; (2) histories of autoim-
mune disorder, peripheral vascular disease, or stroke; (3)
transient ischemic attack, cerebral infarction, and cerebral
hemorrhage; (4) liver failure and acute or chronic kidney
disease; (5) recent myocardial disease in the last 3 months;
(6) medications for lipid control, inflammation suppression,
or immunosuppression; and (7) history of cancer. All exper-
iment protocols were approved by the Department of Neu-
rology at the Ochsner Medical Center and IRB committee
at Wright State University. Written informed consent was
obtained from each participant prior to enrollment in the
study.
2.10. Preparation andAnalyses of Circulating EXs fromHuman
Plasma. Whole blood samples (3mL) were drawn from
ischemic stroke patients at admission day (day 1) and days
3 and 5 after admission using tubes containing 3.13% sodium
citrate.The whole blood samples were diluted 3x with filtered
PBS and centrifuged at 400 g for 35min at 4∘C; the uppermost
layer was collected as plasma. 1mL of plasma was centrifuged
at 2000 g for 20min to remove platelet. The supernatant
was collected and centrifuged at 20,000 g for 70min, and
then the supernatant was ultracentrifuged at 170,000 g for
6 hr to pellet circulating EXs (cEXs). The pelleted cEXs were
resuspended with filtered PBS and then isolated by anti-
CD105- or anti-CD34-conjugated microbeads and analyzed
by NTA. Then, the microbeads captured cEXs were probed
with anti-CD144-, anti-Annexin V-, anti-KDR-, or anti-
CD63-conjugated Q-dots and then subsequently analyzed by
fluorescenceNTA.Theproportion of cEXs using fluorescence
NTAwas calculated as (CD105+Q-dots+) cEXs%=CD105+Q-
dots+ cEXs/total cEXs; (CD34+Q-dots+) cEXs% = CD34+Q-
dots+ cEXs/total cEXs.The absolute number of cEC-EXs and
cEPC-EXs were the absolute counts of CD105+CD144+ cEXs
or CD34+KDR+ cEXs per mL human plasma.
2.11. Statistical Analysis. Experimental data were expressed
as the mean ± SEM and were analyzed using one- or two-
way analysis of variance (ANOVA). The correlation of EX
numbers with their protein concentrations was analyzed
using Spearman’s rank correlation test (SPSS version 17.0;
SPSS, Chicago, IL). Values of 𝑃 < 0.05 were considered to
be of statistical significance.
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Figure 1: Characterization of EC-EXs and EPC-EXs. (a) Representative NTA plot showing the size distribution of 100 nm and 200 nm
polystyrene beads. (b) Representative NTA plots show size/concentration distribution of particles in the EX-depleted EC and EPC medium
and of EC-EXs and EPC-EXs. Black solid line: 100 nm landmark; black dash line: 200 nm landmark. (c) TEM micrographs of EXs. (d)
Representative western blot bands showing the expression of CD63, CD105, and CD34 in EXs and their corresponding parent cells, ECs
and EPCs. (e) The correlation between EXs and their protein concentration.
3. Results and Discussion
3.1. EXs Isolated from EC and EPC Culture Medium Were
Characterized by NTA, TEM, andWestern Blot Analyses. The
Nanosight NS300 system was calibrated with 100 nm and
200 nm polystyrene beads (Figure 1(a)) prior to detecting
experimental samples. As shown in Figure 1(b), there were
only few particles left in the EX-depleted EC medium and
EPC medium. The average size of EC-EXs was 158 ± 55 nm
and of EPC-EXs was 154 ± 59 nm, which were consistent with
previous observations [18, 19]. Meanwhile, our TEM results
were in accordance with the NTA data showing that the EC-
EXs and EPC-EXs were made up of small particles less than
200 nm in diameter (Figure 1(c)). In addition, our western
blot results showed that the EC-EXs and EPC-EXs expressed
CD63 which is one of the protein families most commonly
associated with EXs and is generally used as EX markers [20,
21], further confirming that themicrobeads-isolated particles
were EXs. Meanwhile, it is not surprising to find that EC-EXs
express their parent cell marker CD105 and that EPC-EXs
express EPC specific marker CD34 (Figure 1(d)). In future
studies, other EC and EPC specific markers such as CD31
and CD133 could be tested in EC-EXs and EPC-EXs released
from ECs and EPCs under different conditions, respectively.
As many previous studies used the protein concentration of
EXs, not the particle number, as a quantification parame-
ter for their functional analyses [22–24], we analyzed the
correlation between protein concentration and the particle
number of EC-EXs or EPC-EXs. The correlation coefficient
plots demonstrated that the concentration of EC-EXs and
EPC-EXs detected by NTA highly positively correlated with
their respective protein concentration measured by Bio-Rad
protein assay (Figure 1(e)). This correlation could be applied
to deduce protein concentration from the particle numbers
for in vivo experiments in the future.
3.2. EC-EXs and EPC-EXs Were Isolated by Combining with
Anti-CD105- or Anti-CD34-Conjugated Microbeads and Anti-
CD144- or Anti-KDR-Conjugated Q-Dots. Firstly, in order to
develop the methods, we used EC-EXs derived from cultured
ECs as the standard samples for establishing the isolation
method. And we also confirmed this isolation method by
using EPC-EXs released from cultured EPCs. Because a
panel of markers (CD34, KDR) has been used as surrogate
markers for EPCs [25, 26] and CD105 and CD144 have been
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Figure 2: The efficiencies and specificities of the methods by combining microbeads with NTA for purifying and detecting EC-EXs. (a) The
purification efficiency and specificity of EC-EXs in the total EC-EXs, which were collected from EC culture medium by ultracentrifuge and
isolated by various microbeads-conjugated antibodies against EC specific markers (CD105, as well as negative controls, CD34, CD41, and
CD235a). (b)The detection efficiency and specificity of EC-EXs in the total CD105+ EXs that were labeled with CD144-, or KDR-, or Annexin
V-, or CD63-conjugated Q-dots upon detection by fluorescence NTA. (c)The overall efficiency for measuring the CD105+ EXs colabeled with
CD144-, or KDR-, or Annexin V-, or CD63-conjugated Q-dots in the total EC-EXs. (d) Representative plots showing the size/concentration
distribution of the CD105+ beads isolated EXs under fluorescence/nonfluorescence modes. Black curve: CD105+ EXs measured under light
scatter (nonfluorescence) mode. Yellow curve: CD105+Q-dots+ EXs measured under fluorescence mode. Black dash line: 200 nm landmark.
𝑁 = 4/group.
identified for ECs [27], we used these antibodies to establish
the method. The data showed that anti-CD105-conjugated
microbeads had the highest efficiency (>94%) in purifying
EC-EXs (Figure 2(a)) and anti-CD34-conjugatedmicrobeads
had the highest efficiency (>93%) in purifying EPC-EXs
(Figure 3(a)), when compared to those isolated by negative
controls such as anti-CD41- (specific for platelets) or anti-
CD235a- (specific for erythrocytes) conjugated microbeads.
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Figure 3:The efficiencies and specificities of the methods by combining microbeads with NTA for purifying and detecting EPC-EXs. (a)The
purification efficiency and specificity of EPC-EXs in the total EPC-EXs, which were collected from EPC culture medium by ultracentrifuge
and isolated by variousmicrobeads-conjugated antibodies against EPC specificmarkers (CD34, as well as negative controls, CD105, CD41, and
CD235a). (b)The detection efficiency and specificity of EPC-EXs in the total CD34+ EXs that were labeled with CD144-, or KDR-, or Annexin
V-, or CD63-conjugated Q-dots upon detection by fluorescence NTA. (c)The overall efficiency for measuring the CD34+ EXs colabeled with
CD144-, or KDR-, or Annexin V-, or CD63-conjugated Q-dots in the total EC-EXs. (d) Representative plots showing the size/concentration
distribution of the CD34+ beads isolated EXs under fluorescence/nonfluorescence modes. Black curve: CD34+ EXs measured under light
scatter (nonfluorescence) mode. Yellow curve: CD34+Q-dots+ EXs measured under fluorescence mode. Black dash line: 200 nm landmark.
𝑁 = 4/group.
These results reflect the specificity of CD105 for isolating
EC-EXs and CD34 for isolating EPC-EXs, and they also
further provide proof for the notion that antigen expressed
on EX surface can be used for their selective isolation [28].
After incubation with Q-dots-conjugated antibodies
against CD144 (EC marker), KDR (EPC marker), or CD63,
the purified CD105+ EXs and CD34+ EXs were analyzed
by fluorescence NTA. According to the results of NTA, the





















































































































































































































Figure 4: High recovery and detection efficiency of EC-EXs from particle-free plasma by using microbead purification and fluorescence
NTA detection methods. (a) EC-EXs were recovered from particle-free plasma by using microbeads conjugated with various antibodies and
analyzed by NTA. (b) The detection efficiency of recovered CD105+ EXs that were labeled with secondary antibodies (CD144, or KDR, or
AnnexinV, or CD63) conjugated withQ-dots and analyzed by fluorescent NTA. (c)The overall efficiency formeasuring the recovered CD105+
EXs colabeled with CD144-, or KDR-, or Annexin V-, or CD63-conjugated Q-dots. (d) The absolute number of recovered CD105+ EXs that
were positive for CD144, or KDR, or Annexin V, or CD63 per mL particle-free plasma.𝑁 = 4/group.
detection efficiency of CD105+CD144+ EXs was around 70%
and that of CD105+KDR+ EXs was only around 30% (Fig-
ure 2(b)). Likewise, the detection efficiency of CD34+KDR+
EXs was around 68% and of CD34+CD144+ EXs was only
around 20% (Figure 3(b)). As revealed by the overall effi-
ciency of the EXmeasurement,more than 62%of EXs isolated
from EC culture medium colabeled with CD105 and CD144
(Figure 2(c)). Similarly, the majority (72%) of EXs isolated
from EPC culture medium colabeled with CD34 and KDR
(Figure 3(c)). In order to further exclude the contamination
in particles, we incubated the anti-CD105 or anti-CD34
captured EXs with anti-CD63-conjugated Q-dots or anti-
Annexin V-conjugated Q-dots. The data showed that above
70% of captured EXs were positive for CD63, whereas a
few of them expressed Annexin V, suggesting that there was
a low contamination of MVs in the microbeads captured
EXs. Notably, the size profile of CD105+ EXs (black curve)
overlapped with the Q-dots labeled CD105+ EXs (yellow
curve). Likewise, the size profile of CD34+ EXs (black curve)
overlapped with the Q-dots labeled CD34+ EXs (yellow
curve) (Figures 2(d) and 3(d)). These data indicate that Q-
dots binding did not change the physical characteristics of
EXs.
Collectively, all of these results demonstrate that the
methods combining microbeads and Q-dots with fluores-
cence NTA are able to sensitively and specifically enumerate
EXs from a particle pool.
3.3. EC-EXs and EPC-EXs Were Recovered by Anti-CD105-
or Anti-CD34-Conjugated Microbeads Combined with Anti-
CD144- or Anti-KDR-Conjugated Q-Dots from Particle-Free
Plasma. In order to test the recovery efficiency of EXs from
plasma by using the above described methods, we added a
known amount (6 × 108 particles) of CD105+ EXs or CD34+
EXs into particle-free plasma and then assessed their respec-
tive recovery rate and detection efficiency. As described,
a known amount of EXs (6 × 108 particles) was added
into particle-free plasma, followed by incubation with anti-
CD105-, anti-CD41-, anti-CD235a-, or anti-CD34-conjugated
microbeads. The data showed that almost 90% of added
EC-EXs and EPC-EXs were captured by anti-CD105- (Fig-
ure 4(a)) or anti-CD34-conjugated microbeads (Figure 5(a)),
whereas very few of EXs were captured by anti-CD41
or anti-CD235a (negative controls), further validating the
specificity and sensitivity of the microbeads for capturing
Stem Cells International 9



























































































































































































































Figure 5: High recovery and detection efficiency of EPC-EXs from particle-free plasma by using microbead purification and fluorescence
NTA detection methods. (a) EPC-EXs were recovered from particle-free plasma by using microbeads conjugated with various antibodies
and analyzed by NTA. (b)The detection efficiency of recovered CD34+ EXs that were labeled with secondary antibodies (CD144, or KDR, or
Annexin V, or CD63) conjugated with Q-dots and analyzed by fluorescent NTA. (c)The overall efficiency for measuring the recovered CD34+
EXs colabeled with CD144-, or KDR-, or Annexin V-, or CD63-conjugated Q-dots. (d) The absolute number of recovered CD34+ EXs that
were positive for CD144, or KDR, or Annexin V, or CD63 per mL particle-free plasma.𝑁 = 4/group.
EXs. After incubation with the second antibody and Q-
dots, the NTA results showed that the detection efficiency of
CD105+CD144+ EXs was around 72% and of CD105+KDR+
EXs was around 42% (Figure 4(b)). And the detection
efficiency of CD34+KDR+ EXs was around 69% and of
CD34+CD144+ EXs was only 17% (Figure 5(b)).
As revealed by the overall efficiency of the EX mea-
surement, more than 70% of recovered EC-EXs colabeled
with CD105 and CD144 (Figure 4(c)). Similarly, the majority
(65%) of recovered EPC-EXs colabeled with CD34 and KDR
(Figure 5(c)). Likewise, CD63 and Annexin V were used to
identify whether the particles were EXs. The data indicated
that above 75% of both types of captured EXs were positive
for CD63, but only few were positive for Annexin V, which
was in line with the absolute numbers as shown in Figures
4(d) and 5(d). All of these data were in agreement with the
results we observed in the standard EC-EX and EPC-EX
samples, and they further validated the purification efficiency
and specificity of the established method.
3.4. Isolation of cEC-EXs and cEPC-EXs in Patient Plasma
of Acute Ischemic Stroke by Using Anti-CD105- or Anti-
CD34-Conjugated Microbeads Combined with Anti-CD144-
or Anti-KDR-Conjugated Q-Dots Methods. A previous study
has shown that elevated levels of circulating CD105+CD144+
endothelial-derived extracellularmicrovesicles were found in
plasma from patients with vascular diseases, which indicate
that they could serve as a surrogate marker of endothelial
function [10]. Enumeration and phenotyping of EXs are
important considerations for their use in clinical studies and
in the comparison of EXs from different sources. However,
the nanometer size of EXs harbors the accurate counting
by using flow cytometry [29, 30]. By using the methods
described here, we firstly presented the proof of the concept
of phenotyping EXs from plasma samples.
As shown in Figure 6, approximately 21.8% and 10.8%
of cEXs were captured by anti-CD105- or anti-CD34-con-
jugated microbeads, respectively. With the probe of Q-dots-
conjugated antibodies, we found that about 12% of total cEXs
were CD105+CD144+ cEC-EXs and 7.9% of total cEXs were
CD34+KDR+ cEPC-EXs. Among the collected cEXs, 20%
of them coexpressed CD105 and CD63, and 10.2% of them
coexpressed CD34 and CD63. There was a low percentage
of cEXs expressing Annexin V, reflecting the extremely low
cross-contamination of circulating MVs in the collected
cEXs. There were approximately 1.15 × 107 CD105+CD144+
cEC-EXs and 8.3 × 106 CD34+KDR+ cEPC-EXs per mL
plasma collected from day 1 after patient admission (Figures
6(a3) and 6(b3)).
3.5. Dynamic Changes of cEC-EXs and cEPC-EXs in Patient
Plasma of Acute Ischemic Stroke. Moreover, we assessed
the dynamic changes of CD105+CD144+ cEC-EXs and






































































































































































































































Figure 6: Identification of cEC-EXs and cEPC-EXs from human plasma by using anti-CD105- or anti-CD34-conjugated microbeads and
Q-dots combined with fluorescence NTA. ((a1) and (b1)) The proportions of CD105+ cEXs and CD34+ cEXs in plasma that were isolated by
anti-CD105- or anti-CD34-conjugated microbeads. ((a2) and (b2)) The proportion of CD105+ cEXs or CD34+ cEXs colabeled with CD144-,
or KDR-, or Annexin V-, or CD63-conjugated Q-dots in total cEXs. ((a3) and (b3)) The absolute number of CD105+ cEXs and CD34+ cEXs
that were labeled with CD144, or KDR, or Annexin V, or CD63 per mL day 1 ischemic stroke patient plasma.𝑁 = 8/group.
CD34+KDR+ cEPC-EXs in patients at days 1, 3, and 5 after
admission. As shown in Figure 7, we found that there were
significant elevated levels of CD105+CD144+ cEC-EXs on
days 3 and 5 as compared with that on day 1. The study of
EC-EXs allows us to study the status of the endothelium in
vivo, providing a novel approach that has promising potential
for further understanding of stroke pathophysiology. Mean-
while, this result provides support of EC-EX as a biomarker
of endothelial injury in ischemic stroke.
As analyzed byNTA, there were significant elevated levels
of CD34+KDR+ cEPC-EXs on day 5 as compared with that
on day 1, but there was no difference between days 1 and
3. The increase in EPC-EXs in ischemic stroke may be a
result of increased number of circulating EPCs in response to
ischemia. Taken together, all of these findings will be useful
for developing therapy by using EXs for ischemic stroke.
4. Conclusion
In conclusion, in the present study, we have established sen-





















Day 3Day 1 Day 5
(a)
Figure 7:The dynamic change of cEC-EXs and cEPC-EXs in stroke
patient plasma on days 1, 3, and 5 after admission. (a) The dynamic
change of cEC-EXs and cEPC-EXs per mL plasma on days 1, 3, and
5 after stroke patient admission upon analysis by NTA.
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EXs in cell culture medium and plasma samples. Given their
ease, wide applicability, and high discovery potential, we
believe these methodologies could be an important addition
to the technical repertoire for the qualitative and quantitative
assessment of EXs in a variety of systems, ranging from
cardiovascular to inflammatory diseases.
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